Rare Disease Biotech

The question

Is the current discount on mid-cap rare-disease biotech a rational response to rate-and-reimbursement uncertainty, or is the market extrapolating a single bad cohort of 2023-2024 clinical readouts into a structural de-rating of a reference class that has, on long data, compounded orphan franchise cash flows at rates well above the cost of capital?

Base rates

The reference class is orphan and ultra-rare NDA/BLA submissions since 2010. FDA approval rates for NME filings with orphan designation have run near 84% at the Phase 3-to-approval transition, versus roughly 63% for non-orphan NMEs. Time from filing acceptance to PDUFA action has a median near ten months, with priority review at six. Post-launch, orphan franchises reach peak sales in year five on median, with loss-of-exclusivity timelines that extend well past small-molecule averages because of biologic composition and method-of-use protection stacks.

Equity base rates are less kind. A diversified basket of mid-cap biotech between $1B and $15B in market capitalization has trailed the S&P 500 by roughly 400 basis points annualized over the last decade, and by a much wider gap over the trailing twelve months. Healthcare overall has underperformed SPY by a material margin over the last year, and rare-disease biotech specifically has underperformed healthcare. We are not hiding from that; we are pricing against it.

The key conditional base rate is this: inside the mid-cap orphan cohort, the sub-basket of companies with an approved anchor asset generating positive gross margin and at least one Phase 3 readout in the next eighteen months has historically generated returns roughly double the broader mid-cap biotech index over three-year holding windows. That is the reference class we are constructing against, not the undifferentiated XBI.

Why consensus is wrong

Consensus treats rare-disease biotech as a duration trade gone wrong. The reasoning goes: higher-for-longer rates hurt long-duration cash flow profiles, IRA price negotiation compresses terminal value, and a handful of high-profile Phase 3 failures have recalibrated priors on clinical risk across the subsector. All three claims contain truth; together they overshoot.

First, the IRA's Medicare negotiation mechanic exempts orphan-designated drugs with a single orphan indication. Several names in this book sit structurally outside the negotiation window for their commercial-relevant years. The market has discounted the sub-sector as if the exemption did not exist.

Second, the Phase 3 failure base rate has not changed. Recent readouts have clustered unfavorably, but the rolling five-year Phase 3 success rate for orphan programs with biomarker-confirmed mechanisms has drifted slightly higher, not lower. The market is reading a small sample and calling it a trend.

Third, the royalty and specialty-pharma layer now prices franchises at cash-flow multiples below those of mature consumer staples, even though orphan royalty streams have demonstrably lower revenue volatility than most staples once a drug is two years post-launch. That mispricing creates the anchor position in the book.

Position construction

The book is built in three clusters.

Cash-flowing anchors (~50%). INCY at ~19.2% is the largest position: an approved oncology and inflammation franchise with cash flow to fund internal programs, trading at a multiple that prices in near-zero pipeline value. RPRX at ~18.0% is the royalty aggregator -- the lowest-variance way to own the orphan reference class, with a portfolio that spans more than a dozen approved orphan and semi-orphan franchises. BMRN at ~11.5% rounds out the anchors with a diversified approved-drug base in enzyme replacement and skeletal dysplasia plus a CNS pipeline that is essentially unpriced.

Platform orphan developers (~30%). IONS at ~13.1% owns the antisense platform with multiple approved products and a partnership book that de-risks the pipeline. BBIO at ~11.8% is built around an approved cardiomyopathy franchise with a pipeline of single-mutation orphan programs. KRYS at ~6.2% owns a commercial topical gene therapy with a defensible manufacturing moat. RARE at ~3.5% covers ultra-rare metabolic indications. SRPT at ~2.5% is sized small to reflect the Duchenne franchise's ongoing label and payer debates.

Optionality and specialty (~20%). KYMR at ~4.8% provides targeted protein degradation exposure with partnership validation. ACAD at ~4.0% owns a CNS franchise with two approved drugs and a Rett syndrome program. XENE at ~3.6% covers epilepsy with a late-stage potassium channel program. MNKD at ~1.9% is the smallest position: an approved inhaled-insulin franchise plus a pulmonary pipeline, sized to reflect commercial execution risk.

Asymmetric payoff

The structure of the book is deliberately right-tailed. In a central case where orphan approval rates revert to the ten-year mean and two of the book's five near-term Phase 3 readouts clear, weighted returns track 15-22% annualized over three years. In the bear case -- rates stay elevated, two readouts fail, and IRA negotiation scope expands -- the anchors (INCY, RPRX, BMRN) limit drawdown to roughly -15%. In the bull case where three or more readouts clear and the cohort re-rates toward historical multiples, returns push past 40% annualized.

At 50% base, 30% bear, and 20% bull weightings, expected value clears the SPY base rate even after the trailing-year underperformance is priced into the starting point. The asymmetry comes from the concentrated-portfolio structure: we own twelve names, not the full index, and the anchors carry the book while the optionality names provide the tail.

Three things that would change our mind

1. A regulatory shift that narrows orphan exclusivity or the IRA orphan exemption in a way that touches multi-indication programs, which would reprice the reference class structurally rather than cyclically.
2. A cluster of three or more Phase 3 failures in biomarker-confirmed orphan programs within a six-month window, which would force a genuine revision of the clinical base rate rather than a sentiment wobble.
3. A sustained rise in real rates above 3% with no corresponding change in drug pricing policy, which would compress the long-duration cash flow multiples beyond what current discounts already embed.

What we're explicitly NOT betting on

We are not betting on any single PDUFA date clearing. We are not betting on a specific M&A premium, though the cohort has historical takeout frequency above the market average. We are not betting on a broad biotech beta trade; the book is not XBI and is not sized to track it. We are not betting on pre-clinical or Phase 1 platform stories, which sit outside the reference class we priced. The thesis requires only that orphan approval rates behave like orphan approval rates have behaved for fifteen years, and that the cash-flowing anchors continue to generate cash. Both are weaker claims than picking winners, and the book is sized accordingly.